Novartis AG
Human mesothelin chimeric antigen receptors and uses thereof
Last updated:
Abstract:
Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor(CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
Status:
Grant
Type:
Utility
Filling date:
19 Dec 2014
Issue date:
5 May 2020